Skip to main content
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. — Investor Relations & Filings

Ticker · SER ISIN · US00848H1086 LEI · 5493005PJ4B0GQ36ED85 US Manufacturing
Filings indexed 474 across all filing types
Latest filing 2025-08-14 Director's Dealing
Country US United States of America
Listing US SER

About Serina Therapeutics, Inc.

https://serinatherapeutics.com/

Serina Therapeutics, Inc. is a biotechnology company that develops novel therapeutics based on its proprietary POZ platform technology. This platform utilizes advanced polyoxazoline (POZ) polymers to create drug delivery systems for small molecule drugs, aiming to improve their therapeutic properties, safety, and efficacy. The technology is designed for programmable and targeted drug delivery to optimize treatments. The company's development pipeline is focused on addressing unmet medical needs in neurological diseases, including Parkinson's disease, as well as pain, cancer, and inflammation. Serina Therapeutics aims to redefine the standard of care by enhancing the performance of new and existing drug candidates.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-08-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2025, by Serina Therapeutics, Inc. It announces the issuance of a press release with financial results for the quarter ended June 30, 2025. The document explicitly states that the press release is furnished as an exhibit and that the information is not "filed" for purposes of Section 18 of the Exchange Act, indicating this is an announcement rather than the full financial report itself. The length of the document is 3519 characters, which is relatively short and consistent with a current report announcing earnings results rather than containing detailed financial statements. The key item is "Item 2.02 Results of Operations and Financial Condition," which typically corresponds to an earnings release announcement. Therefore, this document is best classified as an Earnings Release (ER).
2025-08-11 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-11 English
FORM 4
Director's Dealing
2025-08-06 English
FORM 4
Director's Dealing
2025-07-30 English
FORM 4
Director's Dealing
2025-07-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.